Evaxion presents positive and validating immune data from ongoing phase 2 trial with ai-designed evx-01 vaccine at the asco annual meeting 2024

Copenhagen, denmark, june 03, 2024 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, reported data from its ongoing phase 2 study at the american society of clinical oncology (asco) annual meeting 2024. the data demonstrated vaccine-induced immune response in metastatic melanoma patients treated with the company's ai-immunology™ designed personalized cancer vaccine, evx-01, in combination with an anti-pd1 inhibitor. the evx-01 vaccine targets neoantigens - antigenic sequences derived from cancer mutations - that are displayed on the surface of the cancer cells, allowing the immune system to recognize, attack and eliminate the malignant cells.
EVAX Ratings Summary
EVAX Quant Ranking